The long-term OS related to SBRT was noted in a phase-II randomized trial only in the PD-L1− NSCLC population [42], suggesting that RT, particularly SBRT, modifies PD-L1 expression and thus enhances ICI effectiveness. Here, CD274 is linked to non-small cell lung carcinoma.